Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Trading 07-28 14:09:26 EDT

2.27

+0.04

+1.79%

High2.27	Low2.17	Vol1.13M
Open2.24	D1 Closing2.23	Amplitude4.71%
Mkt Cap1.01B	Tradable Cap597.01M	Total Shares444.00M
T/O2.53M	T/O Rate0.43%	Tradable Shares263.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":2.27,"timestamp":1785262155297,"preClose":2.23,"halted":0,"volume":1130496,"delay":0,"changeRate":0.01793721973094172,"floatShares":263000000,"shares":444000000,"eps":-0.070019,"marketStatus":"Trading","change":0.04,"latestTime":"07-28 14:09:26 EDT","open":2.24,"high":2.27,"low":2.165,"amount":2529472.5906432,"amplitude":0.047085,"askPrice":2.27,"askSize":805,"bidPrice":2.26,"bidSize":3102,"shortable":3,"etf":0,"ttmEps":-0.070019,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785268800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":2.23,"preHourTrading":{"tag":"盘前","latestPrice":2.2765,"preClose":2.23,"latestTime":"08:56 EDT","volume":190,"amount":427.88499699999994,"timestamp":1785243413074,"change":0.0465,"changeRate":0.020852,"amplitude":0.020852},"postHourTrading":{"tag":"盘后","latestPrice":2.23,"preClose":2.23,"latestTime":"19:34 EDT","volume":20074,"amount":44768.0645,"timestamp":1785195248529,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.592035,"impliedVol":1.0868,"impliedVolPercentile":0.4462},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2654104987","title":"Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2654104987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654104987?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:35","pubTimestamp":1785162920,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on July 24. Joseph Pantginis has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-advancing-cardiometabolic-pipeline-and-phase-3-hcm-data-support-unchanged-6-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-advancing-cardiometabolic-pipeline-and-phase-3-hcm-data-support-unchanged-6-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCM","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043311","title":"Lexicon completes enrollment in SONATA-HCM study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043311?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:15","pubTimestamp":1785158142,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced that randomization of patients has been completed in the pivotal Phase 3 “SOtaglifloziN in Patients with SymptomATic obstr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-completes-enrollment-in-sonata-hcm-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-completes-enrollment-in-sonata-hcm-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LXRX","HCM","BK4531","BK4007","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654481250","title":"Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2654481250","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654481250?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157231,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) has completed patient enrollment and randomization in a pivotal phase 3 trial of sotagliflozin in patients with symptomatic obstructive and non-obstructive hypertrophic ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654501015","title":"Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654501015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654501015?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:32","pubTimestamp":1785155525,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Completes Enrollment Of Pivotal Phase 3 Sonata-Hcm Study Of Sotagliflozin In Symptomatic Non-Obstructive And Obstructive Hypertrophic Cardiomyopathy (Hcm)July 27 (Reuters","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUABJDHBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654957010","title":"Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2654957010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654957010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:30","pubTimestamp":1785155402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUABJDHBD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648834526","title":"How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648834526","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648834526?lang=en_us&edition=fundamental","pubTime":"2026-07-02 03:44","pubTimestamp":1782935047,"startTime":"0","endTime":"0","summary":"On 27 June 2026, Lexicon Pharmaceuticals, Inc. was added to a wide range of Russell indexes, including the Russell 2000, Russell 2500, Russell 3000 and related growth, microcap and completeness benchmarks, significantly expanding its presence across these index families.\nThis broad index inclusion increases Lexicon’s visibility with institutional investors and index-tracking funds, potentially affecting trading volumes, ownership mix, and how the market assesses its pipeline-driven...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/how-lexicon-pharmas-expanded-russell-index-footprint-shapes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/how-lexicon-pharmas-expanded-russell-index-footprint-shapes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","ARTY","BK4007","AIPO","BK4211","LXRX","CHAT","AGIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927901","title":"Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640927901?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:05","pubTimestamp":1780488329,"startTime":"0","endTime":"0","summary":"Lexicon outlined plans to present new clinical data on sotagliflozin in Type 1 diabetes, ahead of a targeted mid-2026 NDA resubmission.The results will be presented at the ADA 2026 Scientific Sessions on June 7, 2026 in New Orleans.The sotagliflozin analysis points to consistent blood-sugar improvement across patient subgroups, supporting the drug’s mechanistic profile in Type 1 diabetes.Separate ADA data on pilavapadin indicate kidney function did not meaningfully change the drug’s exposure, supporting broad use in diabetic nerve pain studies.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL6qHQ6t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","BK4112","SG9999014005.SGD","BK4139","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4007","LU2095319765.USD","IE00BGHQF748.EUR","BK4588","NDAQ","IE00BN0W2V16.EUR","SG9999014039.USD","LXRX","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","LU0314104364.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640938169","title":"Lexicon Pharmaceuticals’ Earnings Call Highlights Milestone-Fueled Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2640938169","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640938169?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:10","pubTimestamp":1780359038,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (($LXRX)) has held its Q1 earnings call. Read on for the main highlights of the call. Lexicon Pharmaceuticals’ latest earni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-earnings-call-highlights-milestone-fueled-surge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-earnings-call-highlights-milestone-fueled-surge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693206","title":"Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693206","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693206?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971400,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, May  28, 2026  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.(Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies G","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302843/0/en/Lexicon-Pharmaceuticals-to-Present-at-the-2026-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK4581","BK4585","HCM","HCSG","LXRX","XBI","LU0128526141.USD","XLV","BK4137","BK4139","LU0029874061.USD","LABU","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145709187","title":"Stock Track | Lexicon Pharmaceuticals Soars 5.63% Intraday on Investor Conference Participation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1145709187","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145709187?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:59","pubTimestamp":1778594388,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) saw its stock price soar 5.63% during Tuesday's intraday trading session following a company announcement regarding upcoming investor engagement.The biopharmaceutical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823211","title":"Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:31","pubTimestamp":1778589089,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals management to join fireside chat at 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at Nasdaq World Headquarters in New York City","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL17vWLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","IE00BN0W2T93.GBP","LU2095319765.USD","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","BK4112","SG9999014021.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634223876","title":"Lexicon Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2634223876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634223876?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:19","pubTimestamp":1778512740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 11:19 ET (15:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633430140","title":"Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430140?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:55","pubTimestamp":1778237724,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of $6.00. Joseph Pantgin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-buy-rating-reiterated-as-value-catalysts-build-6-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-buy-rating-reiterated-as-value-catalysts-build-6-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BGSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633102923","title":"Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633102923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633102923?lang=en_us&edition=fundamental","pubTime":"2026-05-08 09:47","pubTimestamp":1778204838,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryLexicon Pharmaceuticals Inc LXRX.OQ reported quarterly breakeven results per share for the quarter ended Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149187","title":"Lexicon Q1 FY26 net loss narrows to $1 million; revenue rises to $21.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149187?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:36","pubTimestamp":1778153781,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals posted revenue of $21.1 million for first-quarter 2026, swinging from $1.3 million a year earlier as $20 million of Novo Nordisk development milestones supplemented $1.1 million of INPEFA net sales.Net loss narrowed to $1 million, or less than $0.01 per share, from a loss of $25.3 million, or $0.07 per share, a year earlier.R&D expense fell to $12.8 million from $15.3 million, due to completion of PROGRESS Phase 2b and licensing of LX9851; SG&A dropped to $9.2 million from $11.6 million on reduced INPEFA marketing and lower personnel costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8y0G5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149381","title":"Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149381","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149381?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:31","pubTimestamp":1778153472,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent.  This is a 13.63 percent decrease over sales of $1.262","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://www.benzinga.com/news/earnings/26/05/52361466/lexicon-pharmaceuticals-q1-sales-1-090m-miss-9-380m-estimate","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52361466/lexicon-pharmaceuticals-q1-sales-1-090m-miss-9-380m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633114984","title":"BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2633114984","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633114984?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153448,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01\n\n\nMay 07 (Reuters) - Lexicon Pharmaceuticals Q1 operating expenses USD 22.098 million.\n\nQ1 operating income USD -996 thousand\nQ1 product revenue USD 1.09 million\nQ1 net income USD -1.043 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX9AB942:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149460","title":"Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149460?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 init","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289862/0/en/Lexicon-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4599","BK4139","IE00BZ1G4Q59.USD","LU1093756168.USD","LU0154236417.USD","IE00BKVL7J92.USD","NVOH","BK4178","LXRX","BK4532","NVOX","BK4585","AAN","NVO","LU1093756325.SGD","HCM","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633168005","title":"Lexicon Pharmaceuticals Secures New Hercules Term Loan Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2633168005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633168005?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:38","pubTimestamp":1778103538,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) just unveiled an announcement. On May 4, 2026, Lexicon Pharmaceuticals entered a loan and security agreement wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-secures-new-hercules-term-loan-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-secures-new-hercules-term-loan-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633151522","title":"Lexicon enters USD 100 million loan facility with Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633151522","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633151522?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:07","pubTimestamp":1778098062,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals entered loan facility with Hercules Capital providing up to USD 100 million in borrowing capacity.USD 55 million funded at closing to repay existing Oxford Finance loan facility.Additional USD 20 million tranche available subject to clinical, regulatory, financial milestones; further USD 25 million tranche available after second draw, subject to Hercules consent.Facility carries floating rate at prime plus 3.1% with floor of 9.85%; includes 18-month interest-only period with up to two six-month extensions.Maturity set for May 4, 2030; obligations secured by first-lien interest on all assets with minimum cash covenant starting June 1, 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL5JGpPg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","HTGC","BK4139","BK4135"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.0429},{"period":"1month","weight":-0.1255},{"period":"3month","weight":0.3434},{"period":"6month","weight":0.4867},{"period":"1year","weight":1.0273},{"period":"ytd","weight":0.9391}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0139},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.1601},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.461538,"avgChangeRate":0.013505},{"month":5,"riseRate":0.518519,"avgChangeRate":0.041126},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133521},{"month":7,"riseRate":0.481481,"avgChangeRate":0.018068},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction